"Memorial Sloan-Kettering and all those whose lives are touched by the pioneering work conducted here will be forever grateful to Mort Zuckerman for this wonderful gift," said Douglas A. Warner III, chairman of the Center's Boards of Overseers and Managers. "In his role as a Board member, he has proven to be a thoughtful contributor and insightful leader. It seems to me especially fitting that his name will be associated with the discoveries made in these laboratories."
The Center's programs in immunology, molecular pharmacology and chemistry, and cancer biology and genetics are now being moved into the new structure, which will provide researchers with an inspiring, efficient, and state-of-the-art work environment. The Mortimer B. Zuckerman Research Center will also house the newly established Human Oncology and Pathogenesis Program, a major hospital-based initiative in which scientists and physicians work together to translate laboratory findings into clinical investigations with a direct impact on patient care. Shared "core facilities" in areas such as high-throughput screening and nuclear magnetic resonance will provide crucial equipment and technical support for work conducted by multiple programs.
After the building opens in May 2006, work will get underway on a connecting seven-story structure scheduled for completion in 2009. It will add a conference center with a 350-seat auditorium and a number of "dry" laboratories, including space for computational biology. In addition, The Mortimer B. Zuckerman Research Center will provide a permanent home for the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, a new PhD program that offer
Contact: Christine Hickey
Memorial Sloan-Kettering Cancer Center